Latest Updates (2026)
Curated latest news on drug approvals, regulatory updates, M&A deals, and industry developments in the Indian pharmaceutical sector.
Sun Pharma Makes History with Mega Acquisition
Sun Pharmaceutical Industries completed the acquisition of Organon for $11.8 billion, marking the largest overseas acquisition ever executed by an Indian drugmaker. The move significantly expands Sun Pharma’s global footprint in specialty healthcare and women’s health portfolios.
Q2 2026 Deal Values Hit All-Time Highs
Driven largely by major cross-border M&A transactions, total deal value in India’s pharma and healthcare sector touched nearly $14 billion across 65 transactions in Q2. Outbound M&A transactions accounted for over 90% of total deal value, showcasing aggressive international expansion.
“Biopharma SHAKTI” Scheme Rolls Out
The Government of India launched the Biopharma SHAKTI initiative to enhance domestic biomanufacturing capacities, build biopharma clusters, and reduce import dependencies on advanced therapeutic raw materials and active pharmaceutical ingredients (APIs).
Widespread Adoption of Revised Schedule M (GMP) Guidelines
Indian drug manufacturers—including MSME producers—are transitioning to revised Schedule M Good Manufacturing Practices (GMP). The updated framework aligns domestic production with international standards (such as PIC/S and US-FDA norms) to boost global trust in Indian-made medicines.
Shift Toward Biologics, Biosimilars, and Specialty Care
Top players including Dr. Reddy’s, Zydus Lifesciences, Biocon, and Cipla are continuing a structural shift away from standard generic drug reliance, redirecting 7–9% of their revenues into R&D for complex biosimilars, oncology, and precision medicine.
Government Pushes PRIP Scheme to Boost R&D
Under the Promotion of Research and Innovation in Pharma (PRIP) scheme, the government is expanding funding and public-private partnerships (PPPs) to support long R&D cycles, clinical trials, and early-stage drug discovery in academia and startups.
Expansion of India’s Contract Manufacturing (CDMO) Footprint
Leading contract development and manufacturing organisations (CDMOs) like Divi’s Laboratories, Syngene, and Suven are seeing surging international demand as global pharma giants diversify their supply chains beyond China.
AI and Digital Health Integration Accelerate
Major Indian pharmaceutical companies are deploying AI-driven drug discovery tools and predictive supply chain analytics to streamline regulatory filings, accelerate early-phase trials, and reduce manufacturing lead times.
India Pharma 2026 Focuses on Advanced Therapeutics
At the 9th edition of the annual India Pharma 2026 summit organized by the Department of Pharmaceuticals and FICCI, government officials and industry leaders unveiled pathways to position India as a global hub for cell and gene therapy, targeted delivery systems, and next-generation biologics.
Market Capitalisation Milestones
India’s top pharmaceutical firms recorded strong market valuations on domestic exchanges. Sun Pharma leads the industry with a market cap exceeding ₹4.4 lakh crore, followed by Divi’s Laboratories (~₹1.8 lakh crore), Cipla, and Dr. Reddy’s Laboratories.